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Abstract When following Vogt–Koyanagi–Harada
disease (VKH), indocyanine green angiography
(ICGA) is crucial in the subacute and convalescent
stages of the disease in order to detect subclinical
choroiditis and prevent the development of ‘sunset
glow’ fundus. Hypofluorescent dark dots (HDDs)
indicate persisting granulomas in the choroid. How-
ever, probably as a result of the healing process of
choroidal granulomas, stromal choroidal fibrosis can
also be shown by HDDs. We present two cases where
intravenous corticosteroid administration because of
persistent HDDs led to resolution of lesions in one
case while they persisted in the other case. We
reviewed the medical history of two VKH patients.
Complete routine work-up for patients with posterior
uveitis was performed. The charts were screened for
the presence of HDDs by ICGA in the subacute and
convalescent stages of the disease before and after
administration of body weight-adapted pulse intrave-
nous methylprednisolone (PIM). The evolution of
HDDs was studied and compared in both patients. A
female patient presented with a persistent bilateral
granulomatous panuveitis compatible with VKH.
Cerebrospinal fluid analysis had shown lymphocytic
pleocytosis. At presentation, therapy consisted of oral
prednisone 80 mg/day. Prednisone was tapered down
to 22 mg/day over 3 months, when a recurrence
occurred with the presence of disseminated HDDs.
PIM was administered, followed by oral corticoste-
roids. After 8 days of therapy, ICGA showed an
almost complete disappearance of HDDs. A girl
presented with bilateral panuveitis and widespread
depigmented areas of her fundus. Cerebrospinal fluid
analysis showed monocytic pleocytosis. Because of
relative resistance to oral inflammation suppressive
therapy (IST), PIM was administered for 3 days.
Nevertheless, ICGA showed persistence of HDDs.
Therapy was continued, and 3 months later, a follow-
up ICGA still depicted numerous HDDs. Another PIM
course was given, which had no effect on ICGA signs.
HDDs in this case were interpreted as stromal
choroidal scars. ICGA-guided therapy (mainly HDD
evolution monitoring) helps to eradicate occult stro-
mal disease in VKH and avoids ‘sunset glow’ fundus,
by allowing precise adjustment of therapy. In some
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cases, HDDs do not represent active lesions but
presumed intrastromal scars which need to be identi-
fied. A limited course of maximal IST including PIM
can unmask such cases and avoid overtreatment of
these patients.
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Introduction
Vogt–Koyanagi–Harada disease (VKH) is a systemic
disease with bilateral ocular involvement caused by an
interleukin-2 family-driven Th17 response against
tyrosinase family proteins in melanocytes [1–3]. Since
these antigens, in the posterior segment, are exclu-
sively found in the choroidal stroma, VKH should be
classified as a ‘primary stromal choroiditis’, because
choroidal inflammation is specifically directed at
elements of the choroidal stroma. Only when choroi-
dal inflammation spills over into neighbouring struc-
tures, manifestations like multifocal exudative non-
rhegmatogenous retinal detachments occur around the
optic disc and in the posterior pole [4, 5]. Indocyanine
green angiography (ICGA) is especially suited to
monitor choroidal involvement because it can detect
preclinical choroidal inflammatory lesions before they
spread, as well as persistent choroidal inflammation
after apparent clinical disease has been mastered
[6, 7]. The most important ICGA sign in VKH is
clearly the occurrence of hypofluorescent dark dots
(HDDs), a result of diffusion impairment of the ICG
molecule in the choroidal stroma due to space-
occupying lesions. They are best visible in the
intermediate and late phases of the ICGA and indicate
stromal granulomas as shown by histopathology [8].
Other reliable ICGA signs for evaluation and for
follow-up include hyperfluorescent choroidal vessels,
fuzzy indistinct large stromal vessels indicating cho-
roidal vasculitis, late diffuse hyperfluorescence and,
lastly, ICGA disc hyperfluorescence in cases of
hyperacute disease. Those ICGA signs were seen in
almost 100 % of fresh, de novo, untreated cases [9]. In
recurrent attacks the same signs can be observed.
However in chronic smouldering disease only HDDs
and fuzzy indistinct choroidal vessels indicate ongo-
ing occult choroidal inflammation [10, 11]. During
this stage, no other clinical signs appear. This
subclinical evolution can very well explain the
development of ‘sunset glow’ fundus despite (subop-
timal) therapy. ‘Sunset glow’ fundus, still considered
to be the natural course of the disease, is simply the
result of insufficiently treated disease [6, 7, 12, 13].
When following VKH with the help of ICGA for
optimal therapy in the subacute and convalescent
stages of the disease and in order to prevent the
development of ‘sunset glow’ fundus, HDDs are the
essential parameter to allow optimal adjustments to
treatment of subclinical disease.
HDDs usually represent active stromal choroidal
granulomas; however, they can also image stromal
choroidal fibrosis probably as a result of the healing
process of choroidal granulomas. This work aims to
show that active HDDs can be differentiated from
scarred lesions.
Methods
We reviewed the medical history of two patients who
were examined, treated and followed at the Centre for
Ophthalmic Specialized Care (COS), Lausanne, Swit-
zerland, between 1995 and 2012. Case 1 presented in
August 1995 and Case 2 in November 2005, both
being referred with sight-threatening posterior uveitis
suspected to be due to VKH. Ocular examination
included best-corrected visual acuity, intraocular
pressure (IOP) measurement, grading of intraocular
inflammation using both classical criteria as well as
laser flare photometry [14, 15]. Optical coherence
tomography, fluorescein angiography (FA), ICGA,
and cerebrospinal fluid (CSF) analysis as well as
auditory tests were performed when deemed appro-
priate. Both patients underwent complete laboratory
routine work-up applied to patients with posterior
uveitis. The study was performed in accordance with
the declaration of Helsinki.
The charts were screened for HDDs in ICGA in the
subacute stage of the disease before and after admin-
istration of body weight-adjusted pulse intravenous
methylprednisolone (PIM; Solu-Medrol; Pfizer AG,
Zurich, Switzerland). The evolution of HDDs was
studied and compared in both patients.




A female South American patient was referred at the
age of 24 for a second opinion with a persistent bilateral
granulomatous panuveitis compatible with VKH.
Onset of uveitis had been diagnosed 3 months earlier
in another ophthalmology department. CSF analysis
had shown lymphocytic pleocytosis. No other systemic
signs were found. Further investigations excluded
infectious or neoplastic etiologies. At presentation in
our center, the patient was receiving 80 mg prednisone
per day. Laser Flare Photometry (LFP) measured
8.0 ph/ms in the right eye and 6.0 ph/ms in the left eye.
FA revealed optic disc hyperfluorescence, and ICGA
demonstrated remaining disseminated HDDs. Corti-
costeroids were then slowly tapered. At a dosage of
22 mg/day, inflammation flared up again leading to a
granulomatous anterior uveitis, vitritis and peripheral
exudative detachments. LFP showed increased values
to 28.8 ph/ms in the right eye and 33.2 ph/ms in the left
eye. ICGA showed multiple HDDs in the fundus,
whereas FA did not show gross alterations (Fig. 1).
PIM was administered 1 g/day for 4 days, followed by
oral corticosteroids. Concomitantly, immunosuppres-
sive therapy with cyclosporine A (Sandimmune;
Novartis, Basel, Switzerland) 5 mg/kg body weight
per day was introduced. Eight days after starting this
regime (4 days after PIM), ICGA showed almost
complete disappearance of HDDs (Fig. 1). Prednisone
was tapered to 7.5 mg/day without a flare up for more
than 1 year, when another recurrence occurred. During
the follow-up, an aseptic necrosis of the femoral head
occurred, leading to a hip replacement. This patient
was left under prolonged immunosuppressive therapy
including cyclosporine A and azathioprine (Imurek;
Pro Concepta, Zug, Switzerland) 2.3 mg/kg body
weight per day, finally resulting in a quiet stage
without HDDs 4 years after starting immunosuppres-
sive therapy, without recurrence after discontinuation
of therapy during a follow-up of 8 years, and could be
considered to be ‘healed’.
Case 2
A 16-year-old girl presented elsewhere with decreased
vision on both sides, accompanied by headaches.
Clinical examination revealed anterior chamber
inflammation with granulomatous keratic precipitates,
posterior synechiae, vitreous inflammation and optic
disc hyperemia. IOP was 8 mmHg in the right eye and
7 mmHg in the left eye. Fundus examination showed
diffuse bilateral depigmentation, compatible with
‘sunset glow’ fundus (Fig. 2). FA showed optic disc
hyperfluorescence, faint, barely visible peripheral
leakage, but no pinpoint lesions (leakage) at the
posterior pole. On ICGA, multiple HDDs could be
seen at the posterior pole and mid-periphery indicating
stromal choroidal granulomas. Lumbar puncture
showed CSF pleocytosis with increased intracranial
pressure. Further investigations excluded infectious or
neoplastic etiologies.
At referral to our center 6 weeks after presentation
elsewhere and 6 weeks after starting oral corticoste-
roids (50 mg/day), LFP measured 38.9 ph/ms in the
right eye and 84.6 ph/ms in the left eye. Ultrasound
biomicroscopy showed widespread supracilliary effu-
sion associated with acute myopisation (-2.0 diop-
ters). Since there was no improvement after several
days of oral corticosteroids, PIM was administered
500 mg/day for 3 days. Concomitantly, azathioprine
2.3 mg/kg body weight was started. After PIM,
another ICGA showed numerous persisting HDDs.
Therapy was continued, and a follow-up ICGA was
performed after 3 months (Fig. 3). Numerous HDDs
could still be seen at the identical locations compared
with prior examinations, and the question arose
whether these lesions were active or might represent
choroidal scars. Another PIM course was given, which
had virtually no effect on ICGA signs (Fig. 3). The
failure of HDDs to respond to PIM together with the
presence of hypopigmented fundus lesions strongly
suggested cicatricial lesions in the choroidal stroma.
Unless new HDDs were identified on subsequent
angiographies, which was not the case, ICGA findings
in this case should not be interpreted as persistence of
choroiditis and should not be taken in account to
justify increase of therapy unlike in Case 1 and in most
cases of VKH, where persistence of HDDs means
persistence of active subclinical choroiditis.
Discussion
The two principal difficulties in the treatment of VKH
patients are on one hand the deferred initiation of
therapy because of diagnostic delay and on the other






caused by active disease.





(FA) frame (FA before) only
showing diffuse
irregularities at the level of
the retinal pigment
epithelium. Four days after a
3-day course of intravenous
methylprednisolone (500
mg/day) most of the HDDs
have disappeared or are only
faintly visible (ICGA after);
please note the restoration to
a quasi normal aspect of the





Fig. 2 Fundus photography of Case 2 suffering from VKH, showing ‘‘sunset glow’’ fundus in both eyes
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hand the classical treatment strategy put forward in
most textbooks and publications that is purely based
on the evolution of the clinically apparent extra-
choroidal disease [16]. The treatment regimen pub-
lished and practiced for VKH is now known to be
insufficient as far as dose, duration and addition of
immunosuppressants are concerned [13, 16–18]. In
our opinion, VKH therapy should include the follow-
ing three phases—(1) treatment of the uveitic acute
exudative stage of the disease, (2) monitoring of the
resolution of choroidal inflammation with the help of
ICGA in the subacute stage of the disease (first
4 months of disease), and (3) ICGA-assisted tapering
of therapy with re-increase of therapy at each
subclinical ICGA-detected recurrence of choroidal
inflammation during post-acute stages.
As long as a minimal threshold corticosteroid
therapy is used in the acute phase, the type of
treatment (with or without PIM) could not be shown
to determine the final outcome [17]. The disease stages
for which adequate treatment is of utmost importance
are (2) the subacute stage when extra-choroidal
disease is under control and regression of occult
choroidal lesions is occurring and (3) the subsequent
convalescent stage when occult recrudescence of
choroiditis can occur at a time when IST is very low
or has been discontinued [18]. ICGA monitoring for
these phases has been published previously [19].
During these stages, clinical signs are mostly absent
in insufficiently treated VKH patients, while subclin-
ical choroiditis is progressing, resulting in ‘sunset
glow’ fundus in almost 100 % of cases This occult
smouldering disease can be detected by ICGA and
‘cured’ in a large proportion of patients if treatment is
adjusted accordingly. This is more often the case in
those patients treated early, i.e., a few days to a few
weeks after the onset of an inaugural inflammatory
episode [6].
The only way to monitor occult choroiditis is the
use of ICGA and in order to optimize treatment,
ICGA-guided management has been proposed [6, 19].
The principal ICGA signs used to monitor therapy are
HDDs. In the majority of cases, HDDs indicate active
choroiditis. In rare instances, however, HDDs can be
the result of choroidal scarring. If this is suspected, in
cases of failure of HDDs to resolve despite adequately
dosed IST, it is important to identify the cicatricial
character of these ICGA lesions in order not to
Fig. 3 Case 2: Persistence






choroidal scars rather than
active lesions. The
fluorescein angiographic
(FA) frames show no change
before and after intravenous
methylprednisolone
therapy. The ICGA frames
show that only some
macular HDDs resolve after
intravenous
methylprednisolone
therapy, indicating that all
other HDDs correspond to
choroidal scars. Images are
obtained with the Staurenghi
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overtreat patients. Very often the resolution of all
other ICGA signs such as fuzziness of choroidal vessel
aid in diagnosing the absence of choroiditis despite the
presence of HDDs, but sometimes reinstitution of
maximal therapy is necessary to test whether or not
HDDs resolve.
Administration of high-dose PIM for diagnostic
purposes might raise the question of safety. Severe
adverse events are reported, like sight-threatening rise
of IOP [20], infections [21], bone loss [22] or even
sudden death due to cardiovascular events [23].
However, in all reports it is underscored that these
events are rare [24, 25]. For our purpose, PIM is
sometimes justified since this is a valuable approach to
treat recurrence of the disease. In case of choroidal
scarring, the long-term benefit of not overtreating
patients certainly supersedes the possibility of adverse
events due to treatment with PIM.
In conclusion, ICGA-guided therapy helps to
eradicate occult stromal disease in VKH and may
avoid ‘sunset glow’ fundus, by allowing precise
adjustment of therapy. In some cases HDDs do not
represent active lesions but presumed intrastromal
scars—a fact which needs to be identified. Maximal
IST including PIM allows identification of such cases
and avoids overtreatment of these patients.
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